Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital

NCT05970471 | Completed

• 1 other identifier: 2023/790
• Study Type: observational
• Target: 167
• Locations: 1 country
• Sites: 1

Brief Summary

To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to know who to refer to in case of a serious adverse effect, perform a pharmaceutical analysis of the prescription, and participate in the improvement and evaluation of overall compliance. OPCs are conditioned by the needs, expectations, and involvement of the patients in their care. In healthcare, patients are increasingly encouraged to play an active role in the knowledge and management of their health, express their concerns and preferences, and participate in medical decisions. Thus, it is essential to elicit their preferences. The discrete-choice experiment (DCE) is the validated and recommended method of the International Society for Pharmacoeconomics and Outcomes Research for such a task.

Conditions

Preference, Patient; Pharmacist-Patient Relations; Caregiver; Cancer

Keywords

Preference, Patient; Pharmacist-Patient Relations; Cancer of Colon; Cancer, Breast; Lung Cancer; Prostate Cancer; Renal Cancer; caregiver

Outcome Measures

Primary Outcomes (1)

• Preferences of patients

  utility associated with each attribute

  12 months

Secondary Outcomes (1)

• Preferences of cargivers and healthcare profesionnals

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

240 patients - 60 Caregivers - 360 healhcare professionnals (pharmacist, oncologists, general practitioners)

You may qualify if:

• Patients with lung, prostate breast, prostate or renal cancer;
• Patients with oral cancer drugs;
• Patients accepted to take par in pharmaceutical consultation in hospital.

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Besancon: lead

Study Sites (1)

CHU de Besançon

Besançon, 25030, France

Location

MeSH Terms

Conditions

Patient Preference; Neoplasms; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Kidney Neoplasms

Condition Hierarchy (Ancestors)

Patient Satisfaction; Treatment Adherence and Compliance; Health Behavior; Behavior; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Urologic Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Kidney Diseases; Urologic Diseases

Study Officials

• Virginie NERICH, PhD

  CHU de Besançon

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2023
• First Posted: August 1, 2023
• Study Start: August 10, 2023
• Primary Completion: December 4, 2025
• Study Completion: December 4, 2025
• Last Updated: December 12, 2025

Record last verified: 2025-12

Locations

FR (1)